Major adverse cardiovascular event

Last revised by Joachim Feger on 11 Dec 2021

A major adverse cardiovascular event (MACE), forming part of the larger category of major adverse clinical events, refers to a combined or composite clinical endpoint that is used for outcome evaluations in clinical trials for cardiovascular research. A major adverse cardiovascular/clinical event is employed as a surrogate measure of the safety and effectiveness of a particular intervention.

In the context of percutaneous coronary interventions (PCI), a major adverse cardiovascular event has been defined as being one of the following 1,2:

Since there is no standard definition of other adverse cardiovascular outcomes as e.g. stroke, heart failure, recurrent angina 1,2

History and etymology

The term MACE seems to have originated in the 1990s and was initially developed to relate primarily to percutaneous coronary interventions 1-3. Although the terms "adverse cardiac event" and "adverse clinical event" predated MACE by several years, the former first appearing as a trial endpoint in the early 1980s and the latter in the late 1980s 5,6.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.